{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T16:51:54Z","timestamp":1761238314226,"version":"3.32.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,7,28]],"date-time":"2016-07-28T00:00:00Z","timestamp":1469664000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Saudi Pharmaceutical Journal"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.jsps.2016.07.005","type":"journal-article","created":{"date-parts":[[2016,7,31]],"date-time":"2016-07-31T00:40:01Z","timestamp":1469925601000},"page":"280-289","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Changing paradigms in bioequivalence trials submitted to the EMA for evaluation \u2013 A clinical and regulatory perspective"],"prefix":"10.1007","volume":"25","author":[{"given":"Nathaniel","family":"Refalo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Chetcuti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy","family":"Tanti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Serracino-Inglott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John Joseph","family":"Borg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"unstructured":"Committee for Medicinal Products for Human Use (CHMP), European Public Assessment Report \u201cOlanzapine Cipla\u201d. Procedure No.: EMEA\/H\/C\/000793. <http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Scientific_Discussion\/human\/000793\/WC500042687.pdf> (accessed May 18, 2015).","key":"10.1016\/j.jsps.2016.07.005_b0005"},{"unstructured":"Committee for Medicinal Products for Human Use (CHMP), European Public Assessment Report \u201cZalasta\u201d Procedure No.: EMEA\/H\/C\/000792. <http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Scientific_Discussion\/human\/000792\/WC500045948.pdf> (accessed May 18, 2015).","key":"10.1016\/j.jsps.2016.07.005_b0010"},{"unstructured":"Committee for Medicinal Products for Human Use (CHMP). European Public Assessment Report \u201cIfirmasta\u201d. Procedure No.: EMEA\/H\/C\/000962. EMA Document No.: EMEA\/605953\/2008. <http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/000962\/WC500035271.pdf> (accessed May 18, 2015).","key":"10.1016\/j.jsps.2016.07.005_b0015"},{"unstructured":"Committee for Medicinal Products for Human Use (CHMP), European Public Assessment Report \u201cOlanzapine Mylan\u201d. Procedure No.: EMEA\/H\/C\/961. EMA Document No.: EMEA\/507381\/2008. <http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/000961\/WC500040803.pdf> (accessed May 18, 2015).","key":"10.1016\/j.jsps.2016.07.005_b0020"},{"unstructured":"Committee for Medicinal Products for Human Use (CHMP). European Public Assessment Report \u201cIrbesartan Teva\u201d. Procedure No.: EMEA\/H\/C\/001093. EMA Document No.: EMA\/729732\/2009. <http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/001093\/WC500036108.pdf> (accessed May 18, 2015).","key":"10.1016\/j.jsps.2016.07.005_b0025"},{"unstructured":"Committee for Medicinal Products for Human Use (CHMP), European Public Assessment Report \u201cOlanzapine Glenmark\u201d. Procedure No.: EMEA\/H\/C\/001085. EMA Document No.: EMEA\/774038\/2009. <http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/001085\/WC500070065.pdf> (accessed May 18, 2015).","key":"10.1016\/j.jsps.2016.07.005_b0030"},{"unstructured":"Committee for Medicinal Products for Human Use (CHMP). European Public Assessment Report \u201cOlanzapine Glenmark EU\u201d. Procedure No.: EMEA\/H\/C\/001086. EMA Document No.: EMEA\/774070\/2009. <http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/001086\/WC500070070.pdf> (accessed May 18, 2015).","key":"10.1016\/j.jsps.2016.07.005_b0035"},{"unstructured":"Committee for Medicinal Products for Human Use (CHMP). European Public Assessment Report \u201cOlazax\u201d. Procedure No.: EMEA\/H\/C\/001087. EMA Document No.: EMEA\/774081\/2009. <http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/001087\/WC500070076.pdf> (accessed May 18, 2015).","key":"10.1016\/j.jsps.2016.07.005_b0040"},{"unstructured":"Committee for Medicinal Products for Human Use (CHMP). European Public Assessment Report \u201cOlazax Disperzi\u201d. Procedure No.: EMEA\/H\/C\/001088. EMA Document No.: EMEA\/774092\/2009. <http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/001088\/WC500070061.pdf> (accessed May 18, 2015).","key":"10.1016\/j.jsps.2016.07.005_b0045"},{"unstructured":"Committee for Medicinal Products for Human Use. (CHMP). European Medicines Agency: Guideline on the investigation of bioequivalence. Doc.ref CPMP\/EWP\/QWP\/1401\/98 Rev. 1\/ Corr <http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2010\/01\/WC500070039.pdf>. Published 2010. (accessed May 18, 2015).","key":"10.1016\/j.jsps.2016.07.005_b0050"},{"unstructured":"Committee for Medicinal Products for Human Use (CHMP). European Public Assessment Report \u201cIasibon\u201d. Procedure No.: EMEA\/H\/C\/2025. EMA Document No.: EMA\/801304\/2010. <http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/002025\/WC500101690.pdf> (accessed May 18, 2015).","key":"10.1016\/j.jsps.2016.07.005_b0055"},{"unstructured":"Committee for Medicinal Products for Human Use (CHMP). European Public Assessment Report \u201cIbandronic Acid Teva\u201d. Procedure No.: EMEA\/H\/C\/001195. EMA Document No.: EMA\/598319\/2010 <http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/001195\/WC500097557.pdf> (accessed May 18, 2015).","key":"10.1016\/j.jsps.2016.07.005_b0060"},{"unstructured":"Committee for Medicinal Products for Human Use (CHMP). European Public Assessment Report \u201cMyclausen\u201d. Procedure No.: EMEA\/H\/C\/001218. EMA Document No.: EMA\/CHMP\/451012\/2010. <http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/001218\/WC500097856.pdf> (accessed May 18, 2015).","key":"10.1016\/j.jsps.2016.07.005_b0065"},{"unstructured":"Committee for Medicinal Products for Human Use (CHMP), European Public Assessment Report \u201cOlanzapine Apotex\u201d. Procedure No.: EMEA\/H\/C\/001178. EMA Document No.: EMA\/186276\/2010. <http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/001178\/WC500093597.pdf> (accessed May 18, 2015).","key":"10.1016\/j.jsps.2016.07.005_b0070"},{"unstructured":"Committee for Medicinal Products for Human Use (CHMP). European Public Assessment Report \u201cTemomedac\u201d. Procedure No.: EMEA\/H\/C\/001124. EMA Document No.: EMA\/51724\/2010. <http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/001124\/WC500073303.pdf> (accessed May 18, 2015).","key":"10.1016\/j.jsps.2016.07.005_b0080"},{"unstructured":"Committee for Medicinal Products for Human Use (CHMP). European Public Assessment Report \u201cClopidogrel Teva Pharma B.V.\u201d. Procedure No.: EMEA\/H\/C\/001226. EMA Document No.: EMA\/439548\/2011. <http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/001226\/WC500108104.pdf> (accessed May 18, 2015).","key":"10.1016\/j.jsps.2016.07.005_b0100"},{"unstructured":"Committee for Medicinal Products for Human Use (CHMP). European Public Assessment Report \u201cIbandronic Acid Sandoz\u201d. Procedure No.: EMEA\/H\/C\/002367. EMA Document No.: EMA\/CHMP\/94879\/2011. <http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/002367\/WC500109886.pdf> (accessed May 18, 2015).","key":"10.1016\/j.jsps.2016.07.005_b0105"},{"unstructured":"Committee for Medicinal Products for Human Use (CHMP). European Public Assessment Report \u201cTemozolomide Sun\u201d. Procedure No.: EMEA\/H\/C\/002198. EMA Document No.: EMA\/CHMP\/197697\/2011. <http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/002198\/WC500109707.pdf> (accessed May 18, 2015).","key":"10.1016\/j.jsps.2016.07.005_b0110"},{"unstructured":"Committee for Medicinal Products for Human Use (CHMP). European Public Assessment Report \u201cCapecitabine Accord\u201d. Procedure No.: EMEA\/H\/C\/002386. EMA Document No.: EMA\/225644\/2012. <http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/002386\/WC500126899.pdf> (accessed May 18, 2015).","key":"10.1016\/j.jsps.2016.07.005_b0115"},{"unstructured":"Committee for Medicinal Products for Human Use (CHMP). European Public Assessment Report \u201cCapecitabine Medac\u201d. Procedure No.:EMEA\/H\/C\/002568. EMA Document No.: EMA\/711212\/2012. <http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/002568\/WC500135470.pdf> (accessed May 18, 2015).","key":"10.1016\/j.jsps.2016.07.005_b0120"},{"unstructured":"Committee for Medicinal Products for Human use (CHMP). European Public Assessment Report \u201cEcansya\u201d. Procedure No.: EMEA\/H\/C\/002605. EMA Document No.: EMA\/199988\/2012. <http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/002605\/WC500126968.pdf> (accessed May 18, 2015).","key":"10.1016\/j.jsps.2016.07.005_b0125"},{"unstructured":"Committee for Medicinal Products for Human Use (CHMP). European Public Assessment Report \u201cCapecitabine Teva\u201d. Procedure No.: EMEA\/H\/C\/002362. EMA Document No.: EMA\/275974\/2012. <http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/002362\/WC500127290.pdf> (accessed May 18, 2015).","key":"10.1016\/j.jsps.2016.07.005_b0130"},{"unstructured":"Committee for Medicinal Products for Human Use (CHMP). European Public Assessment Report \u201cDesloratadine Ratiopharm\u201d. Procedure No.: EMEA\/H\/C\/002404. EMA Document No.: EMA\/41222\/2012. <http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/002404\/WC500122417.pdf> (accessed May 18, 2015).","key":"10.1016\/j.jsps.2016.07.005_b0135"},{"unstructured":"Committee for Medicinal Products for Human Use (CHMP), European Public Assessment Report- Scientific Discussion \u201cOlanzapine Teva\u201d. Procedure No.: EMEA\/H\/C\/000810. <http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Procedural_steps_taken_before_authorization\/human\/000810\/WC500043255.pdf> (accessed May 18, 2015).","key":"10.1016\/j.jsps.2016.07.005_b0140"},{"unstructured":"Committee for Medicinal Products for Human Use (CHMP). European Public Assessment Report \u201cSabervel\u201d. Procedure No.: EMEA\/H\/C\/002510. EMA Document No.: EMA\/225623\/2012. <http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/002510\/WC500125731.pdf> (accessed May 18, 2015).","key":"10.1016\/j.jsps.2016.07.005_b0145"},{"unstructured":"Committee for Medicinal Products for Human Use (CHMP). European Public Assessment Report \u201cCapecitabine SUN\u201d. Procedure No.: EMEA\/H\/C\/002050\/0000. EMA Document No.: EMA\/370014\/2013. <http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/002050\/WC500145306.pdf> (accessed May 18, 2015).","key":"10.1016\/j.jsps.2016.07.005_b0150"},{"unstructured":"Committee for Medicinal Products for Human Use (CHMP), European Public Assessment Report \u201cActelsar HCT\u201d. Procedure No.: EMEA\/H\/C\/002676\/0000. EMA Document No.:EMA\/163479\/2013. <http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/002676\/WC500140813.pdf> (accessed May 18, 2015).","key":"10.1016\/j.jsps.2016.07.005_b0155"},{"unstructured":"Committee for Medicinal Products for Human Use (CHMP), European Public Assessment Report \u201cTolucombi\u201d. Procedure No.: EMEA\/H\/C\/002549. EMA Document No.: EMA\/84367\/2013. <http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/002549\/WC500141663.pdf> (accessed May 18, 2015).","key":"10.1016\/j.jsps.2016.07.005_b0160"},{"unstructured":"Committee for Medicinal Products for Human Use (CHMP). European Public Assessment Report \u201cImatinib Actavis\u201d. Procedure No.: EMEA\/H\/C\/002594. EMA Document No.: EMA\/CHMP\/86075\/2013. <http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/002594\/WC500143108.pdf> (accessed May 18, 2015).","key":"10.1016\/j.jsps.2016.07.005_b0165"},{"unstructured":"Committee for Medicinal Products for Human Use (CHMP). European Public Assessment Report \u201cRivastigmine 3M Healthcare Ltd.\u201d. Procedure No.: EMEA\/H\/C\/003824. EMA Document No.: EMA\/111203\/2014. <http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/003824\/WC500165292.pdf> (accessed May 18, 2015).","key":"10.1016\/j.jsps.2016.07.005_b0170"},{"unstructured":"Committee for Medicinal Products for Human Use (CHMP). European Public Assessment Report \u201cXeloda\u201d. Procedure No.: EMEA\/H\/C\/000316.","key":"10.1016\/j.jsps.2016.07.005_b0175"},{"unstructured":"Directive 2001\/83\/EC of the European Parliament and of the council of 6 November 2001 on the community code relating to medicinal products for human use as amended. <http:\/\/ec.europa.eu\/health\/files\/eudralex\/vol-1\/dir_2001_83_consol_2012\/dir_2001_83_cons_2012_en.pdf>. Published 2012 (accessed May 18, 2015).","key":"10.1016\/j.jsps.2016.07.005_b0180"},{"key":"10.1016\/j.jsps.2016.07.005_b0185","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/j.1365-2125.2010.03718.x","article-title":"Generic and therapeutic substitutions in the UK: are they a good thing?","volume":"70","author":"Duerden","year":"2010","journal-title":"Br. J. Clin. Pharmacol."},{"unstructured":"Online Medicines database. <http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/landing\/epar_search.jsp&mid=WC0b01ac058001d124> (accessed May 18, 2015).","key":"10.1016\/j.jsps.2016.07.005_b0190"},{"unstructured":"European Medicines Agency. European public assessment reports: background and context. Ema.europa.eu. <http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/general\/general_content_000433.jsp&mid=WC0b01ac058067fa25> (accessed May 18, 2015).","key":"10.1016\/j.jsps.2016.07.005_b0195"},{"key":"10.1016\/j.jsps.2016.07.005_b0200","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1377\/hlthaff.2010.0270","article-title":"Evolving brand-name and generic drug competition may warrant a revision of the Hatch-Waxman Act","volume":"30","author":"Grabowski","year":"2011","journal-title":"Health Affair."},{"key":"10.1016\/j.jsps.2016.07.005_b0205","first-page":"462","article-title":"Encouraging the use of generic medicines: implications for transition economies","volume":"43","author":"King","year":"2002","journal-title":"Croat Med. J."},{"issue":"1","key":"10.1016\/j.jsps.2016.07.005_b0210","doi-asserted-by":"crossref","first-page":"274","DOI":"10.22237\/jmasm\/1335846240","article-title":"Four period crossover designs","volume":"11","author":"Reed","year":"2012","journal-title":"J. Mod. App. Stat. Meth."},{"key":"10.1016\/j.jsps.2016.07.005_b0215","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1162\/0034653053327694","article-title":"Generic drug industry dynamics","volume":"87","author":"Reiffen","year":"2005","journal-title":"Rev. Econ. Stat."}],"container-title":["Saudi Pharmaceutical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1319016416300731?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1319016416300731?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T17:29:58Z","timestamp":1736184598000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1319016416300731"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["S1319016416300731"],"URL":"https:\/\/doi.org\/10.1016\/j.jsps.2016.07.005","relation":{},"ISSN":["1319-0164"],"issn-type":[{"type":"print","value":"1319-0164"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Changing paradigms in bioequivalence trials submitted to the EMA for evaluation \u2013 A clinical and regulatory perspective","name":"articletitle","label":"Article Title"},{"value":"Saudi Pharmaceutical Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsps.2016.07.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University.","name":"copyright","label":"Copyright"}]}}